
    
      Patients receive itraconazole oral solution twice daily. Per 08/15/94 amendment, patients
      with complete resolution of oropharyngeal candidiasis lesions upon completion of treatment
      are eligible for maintenance treatment on protocol FDA 236C. Patients who decline maintenance
      are followed for 6 weeks. Patients who relapse during follow-up are re-treated for 14-28
      days; if lesions clear, patients may enter the maintenance protocol.
    
  